Durect corp

Financial Times Close. Search the FT Search. Show more World link World.

DURECT harnesses epigenetic modulation to treat serious and life-threatening conditions, including acute organ injury and cancer. Many types of acute organ injuries and cancers are associated with dysregulation of the epigenome, such as DNA methylation. There is vast potential for epigenetic therapies to address the underlying pathophysiology by mitigating epigenomic dysregulation and helping to improve cellular function or suppress tumor growth. Join our highly experienced, talented, and collaborative team as we strive to improve the course of human medicine with novel epigenetic therapies. Brown, President and Chief. Unlocking the potential of epigenetic therapeutics to revolutionize medicine. Epigenetic Modulation.

Durect corp

.

Clin Epigenetics. PLoS One. But opting out of some of these cookies may have an effect on your browsing experience.

.

Management will also host a conference call and webcast with investors to discuss financial results and provide a corporate update at pm Eastern Time. Details for the call are as follows:. Toll Free:. Actual results may differ materially from those contained in the forward-looking statements contained in this press release, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from those projected include, among other things, the risk that future clinical trials of larsucosterol do not confirm the results from subset analyses of the AHFIRM trial, including geographic or other segmentation, or of earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy of larsucosterol in a statistically significant manner, the risk that the FDA or other government agencies may require additional clinical trials for larsucosterol before approving it for the treatment of AH, risks that Innocoll may not commercialize POSIMIR successfully, and risks related to the sufficiency of our cash resources, our anticipated capital requirements and capital expenditures, our need or desire for additional financing, our ability to obtain capital to fund our operations and expenses and our ability to continue to operate as a going concern. All information provided in this press release and in the attachments is based on information available to DURECT as of the date hereof, and DURECT assumes no obligation to update this information as a result of future events or developments, except as required by law. Other referenced trademarks belong to their respective owners.

Durect corp

The pre-funded warrants and the accompanying warrants will be immediately exercisable. The pre-funded warrants do not expire and the accompanying warrants will expire five years from the date of issuance. The closing of the Offering is expected to occur on or about February 8, , subject to customary closing conditions. DURECT intends to use the net proceeds of the Offering for general corporate purposes, which may include clinical trials, research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs. The Offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating to, and describing the terms of, the Offering will be filed with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program.

Property for sale gloucester nsw

Epigenetic Modulation. For more information, see our Privacy Policy. Am J Gastroenterol. We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. Brown, President and Chief. You also have the option to opt-out of these cookies. Our first epigenetic modulator, larsucosterol, may have the potential to save the lives of patients with AH and become a new standard of care, based on outcomes from clinical trials to date. Alcohol-Associated Hepatitis AH. This cookie is set by Rubicon Project to control synchronization of user identification and exchange of user data between various ad services. Press Releases.

Brown , D. We look forward to entering discussions with the U.

Show more Markets link Markets. Manage cookie consent. Show more Opinion link Opinion. Clin Epigenetics. Any information that you receive via FT. Short lived cookies used by Motomo Analytics to temporarily store data for the visit. Add to Your Portfolio New portfolio. Financial Times Close. Show more Companies link Companies. Analytical cookies are used to understand how visitors interact with the website.